Evidence map›Paper›PMID 27376018›Full record

ReviewWorld journal of methodology2016

Methods, units and quality requirements for the analysis of haemoglobin A1c in diabetes mellitus.

Ilkka Penttilä, Karri Penttilä, Päivi Holm, Harri Laitinen, Päivi Ranta, Jukka Törrönen, Rainer Rauramaa

Open access · diamondAbstract readReview
In one paragraph

Review in World journal of methodology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Ilkka PenttiläIlkka Penttilä, Jukka Törrönen, Rainer Rauramaa, Kuopio Research Institute of Exercise Medicine, University of Eastern Finland, 70100 Kuopio, Finland.
Karri PenttiläIlkka Penttilä, Jukka Törrönen, Rainer Rauramaa, Kuopio Research Institute of Exercise Medicine, University of Eastern Finland, 70100 Kuopio, Finland.
Päivi HolmIlkka Penttilä, Jukka Törrönen, Rainer Rauramaa, Kuopio Research Institute of Exercise Medicine, University of Eastern Finland, 70100 Kuopio, Finland.
Harri LaitinenIlkka Penttilä, Jukka Törrönen, Rainer Rauramaa, Kuopio Research Institute of Exercise Medicine, University of Eastern Finland, 70100 Kuopio, Finland.
Päivi RantaIlkka Penttilä, Jukka Törrönen, Rainer Rauramaa, Kuopio Research Institute of Exercise Medicine, University of Eastern Finland, 70100 Kuopio, Finland.
Jukka TörrönenIlkka Penttilä, Jukka Törrönen, Rainer Rauramaa, Kuopio Research Institute of Exercise Medicine, University of Eastern Finland, 70100 Kuopio, Finland.
Rainer RauramaaIlkka Penttilä, Jukka Törrönen, Rainer Rauramaa, Kuopio Research Institute of Exercise Medicine, University of Eastern Finland, 70100 Kuopio, Finland.
Finnish Medicines Agency Fimea · FIFimlab (Finland) · FIUniversity of Eastern Finland · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The formation of glycohemoglobin, especially the hemoglobin A1c (HbA1c) fraction, occurs when glucose becomes coupled with the amino acid valine in the β-chain of Hb; this reaction is dependent on the plasma concentration of glucose. Since the early 1970s it has been known that diabetics display higher values OF HbA1C because they have elevated blood glucose concentrations. Thus HbA1c has acquired a very important role in the treatment and diagnosis of diabetes mellitus. After the introduction of the first quantitative measurement OF HbA1C, numerous methods for glycohemoglobin have been introduced with different assay principles: From a simple mini-column technique to the very accurate automated high-pressure chromatography and lastly to many automated immunochemical or enzymatic assays. In early days, the results of the quality control reports for HbA1c varied extensively between laboratories, therefore in United States and Canada working groups (WG) of the Diabetes Controls and Complications Trial (DCCT) were set up to standardize the HbA1c assays against the DCCT/National Glycohemoglobin Standardization Program reference method based on liquid chromatography. In the 1990s, the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) appointed a new WG to plan a reference preparation and method for the HBA1c measurement. When the reference procedures were established, in 2004 IFCC recommended that all manufacturers for equipment used in HbA1c assays should calibrate their methods to their proposals. This led to an improvement in the coefficient of variation (CV%) associated with the assay. In this review, we describe the glycation of Hb, methods, standardization of the HbA1c assays, analytical problems, problems with the units in which HbA1c values are expressed, reference values, quality control aspects, target requirements for HbA1c, and the relationship of the plasma glucose values to HbA1c concentrations. We also note that the acceptance of the mmol/mol system for HbA1c as recommended by IFCC, i.e., the new unit and reference ranges, are becoming only slowly accepted outside of Europe where it seems that expressing HbA1c values either only in per cent units or with parallel reporting of percent and mmol/mol will continue. We believe that these issues should be resolved in the future and that it would avoid confusion if mmol/mol unit for HbA1c were to gain worldwide acceptance.

Indexed as

DiabetesGlucoseGlycohemoglobinHemoglobin A1cInternational Federation of Clinical Chemistry and Laboratory MedicineQuality assuranceRecommendationReference valuesTarget limits

Identifiers

PMID27376018
PMCPMC4921944
OpenAlexW2460170583

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.